CYPHERPUNK TECHNOLOGIES INC. CYPH
We were incorporated in the state of Delaware on January 3, 2011. Our wholly owned subsidiaries as of December 31, 2025 include HealthCare Pharmaceuticals Pty Ltd. ("HCP Australia"), Leap Securities Corp., Flame Biosciences LLC, and Leap Therapeutics, Inc. ("Leap").
Prior to October 2025, we devoted substantially all of our resources to development efforts related to biomarker-targeted antibody therapies designed to treat patients with cancer. Our clinical stage program is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1, for the treatment of colorectal cancer patients. We also have a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1.5M | $1.5M | — | — | — | — |
| R&D | $25.7M | $57.2M | $73.2M | $45.0M | $32.2M | $20.4M | $24.4M | $21.8M | $22.5M | $23.3M |
| SG&A | $10.9M | $12.8M | $13.8M | $11.8M | $10.8M | $9.6M | $9.1M | $8.9M | $9.8M | $4.0M |
| Total operating expenses | $41.1M | $70.1M | $87.0M | $56.8M | $42.9M | $30.0M | $33.5M | $30.8M | $32.4M | $27.3M |
| Operating income | -$41.1M | -$70.1M | -$87.0M | -$56.8M | -$41.4M | -$28.5M | -$33.5M | -$30.8M | -$32.4M | -$27.3M |
| Interest expense | $24.0K | — | — | $54.0K | $41.0K | $39.0K | $23.0K | $19.0K | $528.0K | — |
| Pre-tax income | $10.1M | -$67.0M | -$81.4M | -$54.4M | -$40.6M | -$27.5M | -$32.9M | -$23.1M | -$29.9M | -$25.6M |
| Income tax | $5.3M | $585.0K | — | $147.0K | $24.0K | $2.0K | $3.0K | $20.0K | $157.0K | — |
| Net income | $5.0M | -$68.0M | -$81.0M | -$54.6M | -$40.6M | -$27.5M | -$32.9M | -$23.1M | -$29.7M | -$25.6M |
| EPS, basic | 0.07 | -1.81 | -3.98 | -4.82 | -0.47 | -0.63 | -1.47 | -1.64 | -3.27 | — |
| EPS, diluted | 0.07 | -1.81 | -3.98 | -4.82 | -0.47 | -0.63 | -1.47 | -2.11 | -3.31 | — |
| Shares, diluted (wtd. avg.) | $70.7M | $37.6M | $20.4M | $11.3M | $85.8M | $59.3M | $22.6M | $14.4M | $9.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.0M | $47.2M | $70.6M | $65.5M | $114.9M | $52.1M | $3.9M | $16.3M | $25.7M | $793.0K |
| Total current assets | $162.1M | $48.0M | $71.6M | $68.0M | $116.9M | $52.3M | $4.2M | $17.3M | $27.7M | $4.0M |
| Property, plant and equipment | — | $5.0K | $5.0K | $20.0K | $36.0K | $65.0K | $124.0K | $86.0K | $135.0K | $119.0K |
| Total assets | $163.2M | $49.1M | $72.8M | $70.4M | $117.9M | $54.4M | $7.4M | $19.1M | $29.1M | $6.5M |
| Accounts payable | $2.0M | $4.7M | $6.5M | $5.7M | $4.2M | $2.7M | $4.6M | $3.6M | $2.6M | $3.2M |
| Total current liabilities | $4.6M | $14.1M | $12.7M | $11.2M | $10.0M | $7.4M | $8.5M | $6.5M | $6.1M | $36.2M |
| Total liabilities | $9.7M | $14.1M | $12.7M | $11.5M | $10.0M | $7.7M | $9.2M | $9.9M | $17.9M | $36.2M |
| Retained earnings | -$462.5M | -$467.4M | -$399.6M | -$318.2M | -$263.6M | -$223.0M | -$195.2M | -$153.5M | -$130.4M | -$100.7M |
| Total equity | $153.5M | $35.0M | $60.1M | $58.9M | $107.9M | $46.7M | -$1.7M | $9.2M | $11.1M | -$100.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.9M | -$60.3M | -$43.8M | -$49.0M | -$35.2M | -$26.0M | -$26.9M | -$26.0M | -$22.1M | -$25.3M |
| Depreciation and amortisation | $0 | $5.0K | $15.0K | $16.0K | $29.0K | $34.0K | $47.0K | $49.0K | $48.0K | $25.0K |
| Stock-based compensation | $4.9M | $5.5M | $5.1M | $5.2M | $3.7M | $2.6M | $3.7M | $3.5M | $5.6M | $45.0K |
| Capital expenditure | — | — | — | — | — | — | $100.0K | — | $64.0K | $144.0K |
| Investing cash flow | -$97.0M | — | $49.0M | — | — | $25.0K | -$85.0K | — | -$64.0K | -$144.0K |
| Financing cash flow | $107.6M | $37.2M | -$30.0K | -$210.0K | $98.0M | $74.0M | $14.8M | $15.9M | $47.8M | $25.6M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-051480.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |